Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
-
Patent number: 8088384Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.Type: GrantFiled: November 16, 2009Date of Patent: January 3, 2012Assignee: Rinat Neuroscience Corp.Inventors: Jaume Pons, Arnon Rosenthal
-
Patent number: 8088618Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: September 29, 2008Date of Patent: January 3, 2012Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Publication number: 20110318345Abstract: substances and the nasal administration thereof, in particular as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, in particular the posterior region of the nasal airway, and in particular the upper posterior region of the nasal airway, which includes the olfactory bulb, in particular in the treatment of neurological conditions and disorders.Type: ApplicationFiled: September 15, 2009Publication date: December 29, 2011Applicant: OptiNose ASInventor: Per Gisle Djupesland
-
Patent number: 8071099Abstract: The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.Type: GrantFiled: September 27, 2010Date of Patent: December 6, 2011Assignee: ImClone, LLCInventors: Yiwen Li, Dan Lu, David Surguladze, James Robert Tonra
-
Patent number: 8067546Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.Type: GrantFiled: April 19, 2006Date of Patent: November 29, 2011Assignee: Seattle Genetics, Inc.Inventors: Charlotte McDonagh, Paul Carter, Julie McEarchern, Che-Leung Law
-
Patent number: 8067199Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.Type: GrantFiled: December 23, 2004Date of Patent: November 29, 2011Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle, Mason Lu, Changning Yan, Sanjaya Singh, Dan Huang
-
Patent number: 8063188Abstract: Monoclonal anti-myostatin antibodies that preferentially bind myostatin over GDF-11, have strong binding affinity to myostatin and are resistant to chemical degradation. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment or prevention of various disorders in mammalian and avian species.Type: GrantFiled: August 23, 2007Date of Patent: November 22, 2011Assignee: Eli Lilly and CompanyInventors: Robert Owen Sayers, Lihua Huang
-
Patent number: 8062866Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: November 13, 2009Date of Patent: November 22, 2011Assignee: Femta Pharmaceuticals, Inc.Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
-
Publication number: 20110280832Abstract: The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. Thus, provided are pharmaceutical compositions including specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. Also provided are specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing such antibodies.Type: ApplicationFiled: January 28, 2010Publication date: November 17, 2011Applicant: THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH S ERNICES FUND OF THE TEL AVIV MEDICAL CENTERInventors: Jacob George, Gad Keren
-
Patent number: 8057792Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.Type: GrantFiled: March 1, 2010Date of Patent: November 15, 2011Assignee: Sciaticon ABInventors: Kjell Olmarker, Bjorn Rydevik
-
Patent number: 8058400Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: October 22, 2007Date of Patent: November 15, 2011Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard H. Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 8048422Abstract: Anti-Tweak antibodies are described.Type: GrantFiled: November 26, 2007Date of Patent: November 1, 2011Assignee: Biogen Idec MA Inc.Inventors: Linda C. Burkly, Ellen Garber, Alexey Lugovsky
-
Publication number: 20110262449Abstract: The present invention relates to a new method, and the process to manufacture a medicament, for treating gout or pseudogout, comprising administering an effective amount of inhibitors blocking IL-1 or its maturation by the NALP3 inflammasome.Type: ApplicationFiled: July 1, 2011Publication date: October 27, 2011Applicant: TOPOTARGET SWITZERLAND SAInventors: Virginie PETRILLI, Fabio Martinon, Jurg Tschopp, Thibault De Smedt
-
Publication number: 20110256132Abstract: Description of antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. Furthermore, description of the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with anyone or a combination of decreased muscle mass, muscle strength and muscle function.Type: ApplicationFiled: December 18, 2009Publication date: October 20, 2011Inventors: Claire Ashman, Andrew Beaton, Jonathan Henry Ellis, Baijin Han, Ian Kirby, Frederick Kull, Alan Lewis, Kathryn Mason Lindley, Martin Anibal Orecchia, Ying Shen, Paul Wilson, Tian Shun Xun, Hong Zhang
-
Publication number: 20110250210Abstract: The present invention relates to neutralizing antibodies and fragments thereof directed against Platelet Factor-4 variant 1 (PF4v1) and their use for treating pathologies that require induction of angiogenesis or diseases associated with pathological angiogenesis.Type: ApplicationFiled: October 7, 2009Publication date: October 13, 2011Inventors: Andreas Bikfalvi, Alexandre Dubrac, Eric Lacazette, Herve Prats
-
Patent number: 8034337Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.Type: GrantFiled: June 1, 2009Date of Patent: October 11, 2011Assignee: Xbiotech, Inc.Inventor: John Simard
-
Patent number: 8034352Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-?2b.Type: GrantFiled: April 1, 2010Date of Patent: October 11, 2011Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 8034905Abstract: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.Type: GrantFiled: November 7, 2008Date of Patent: October 11, 2011Assignees: Affitech Research, AS, Peregrine Pharmaceuticals, Inc.Inventors: Anita Kavlie, Kyle Schlunegger
-
Patent number: 8034344Abstract: This invention provides fully human monoclonal antibodies that recognize the IL-6/IL-6R complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.Type: GrantFiled: May 13, 2009Date of Patent: October 11, 2011Assignee: NovImmune S.A.Inventors: Walter Ferlin, Marie Kosco-Vilbois, Greg Elson, Olivier Leger, Florence Guilhot
-
Publication number: 20110243936Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: ApplicationFiled: April 29, 2011Publication date: October 6, 2011Inventors: FERNANDO JOSE REBELO DO COUTO, KRISTIN BETH HENDRICKS, STACEY ELLEN WALLACE
-
Patent number: 8026344Abstract: Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: April 9, 2007Date of Patent: September 27, 2011Assignee: MedImmune LimitedInventors: Qing Zhou, Stephen Charles Emery, Paul Elvin
-
Publication number: 20110223178Abstract: The present invention relates to antibodies and related molecules that specifically bind to CK-?4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune disease, inflammatory disorders, immunodeficiencies, infections, HIV, arthritis, allergy, psoriasis, dermatitis, and inflammatory bowel disease. The invention also relates to nucleic acid molecules encoding anti-CK-?4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.Type: ApplicationFiled: January 31, 2011Publication date: September 15, 2011Applicant: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben
-
Patent number: 8017343Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.Type: GrantFiled: October 19, 2006Date of Patent: September 13, 2011Assignee: ZymoGenetics, Inc.Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
-
Patent number: 8017734Abstract: The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (PlGF), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2) and leptin.Type: GrantFiled: September 15, 2008Date of Patent: September 13, 2011Assignee: PerkinElmer LAS, Inc.Inventors: Lucilla Poston, Paul Townsend Seed, Beverley Jane Hunt, Lucy Charlotte Chappell
-
Patent number: 8012477Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of a solid or hematological malignant diseases.Type: GrantFiled: January 30, 2007Date of Patent: September 6, 2011Assignees: Novartis AG, Novartis Pharma GmbHInventors: Michael Cooreman, Franco E. Di Padova
-
Patent number: 8012475Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.Type: GrantFiled: May 14, 2009Date of Patent: September 6, 2011Assignee: Genetics Institute, LLCInventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
-
Patent number: 8012474Abstract: The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.Type: GrantFiled: August 4, 2008Date of Patent: September 6, 2011Assignee: Nov Immune S.A.Inventors: Nicolas Fischer, Marie Kosco-Vilbois, Francois Mach
-
Patent number: 8013123Abstract: The invention relates to the diagnosis of disease based on the presence of biochemical components in human or animal body fluids, tissues and/or biomaterials.Type: GrantFiled: May 11, 2005Date of Patent: September 6, 2011Assignee: B.R.A.H.M.S. GmbHInventors: Andreas Bergmann, Andrea Ernst
-
Publication number: 20110206663Abstract: The present invention relates generally to the generation and characterization of neutralizing anti-IFN-? monoclonal antibodies with broad reactivity against various IFN-? subtypes. The invention further relates to the use of such anti-IFN-? antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-?, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).Type: ApplicationFiled: February 24, 2011Publication date: August 25, 2011Applicant: Genentech, Inc.Inventors: Anan Chuntharapai, Jin K. Kim, Leonard G. Presta, Timothy Stewart
-
Patent number: 8003099Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.Type: GrantFiled: September 29, 2009Date of Patent: August 23, 2011Assignee: Roche Palo Alto LLCInventors: Johannes Auer, Nikolaos Dimoudis, Guy Georges, Petra Hanke, Hendrik Knoetgen, Ekkehard Moessner, Claire Louise Langrish
-
Patent number: 7993878Abstract: An IL-1? binding molecule, in particular an antibody to human IL-1?, especially a human antibody to human IL-1? is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.Type: GrantFiled: September 26, 2008Date of Patent: August 9, 2011Assignee: Novartis AGInventors: Hermann Gram, Franco E Di Padova
-
Patent number: 7994293Abstract: Antibodies specific for Dkk-1, an inhibitor of the osteoanabolic Wnt/LRP5 signaling pathway, are described. The antibodies, which inhibit binding of Dkk-1 to LRP5, are useful in compositions for stimulating bone growth, in particular, compositions for treating bone disorders which result in a loss in bone, for example, osteoporosis.Type: GrantFiled: February 6, 2008Date of Patent: August 9, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Zhiqiang An, Fang Chen, John E. Fisher, Helmut Glantschnig, Donald B. Kimmel, Alfred A. Reszka, Fubao Wang
-
Patent number: 7993645Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: August 12, 2010Date of Patent: August 9, 2011Assignee: Janssen Biotech, Inc.Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
-
Publication number: 20110189082Abstract: Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes.Type: ApplicationFiled: September 18, 2008Publication date: August 4, 2011Inventors: Jacqueline A. Kirchner, Kenneth A. Brasel, Kara Olson, Jose Carlos Escobar, Dauphine Barone
-
Publication number: 20110182892Abstract: The present invention provides methods and kits for improving the progression-free survival of a patient suffering from gastrointestinal cancer and for assessing the sensitivity or responsiveness of the patient to treatment comprising bevacizumab.Type: ApplicationFiled: January 18, 2011Publication date: July 28, 2011Applicant: Hoffman-La Roche. Inc.Inventors: Paul Delmar, Dorothee Foernzler, Stefan Scherer
-
Publication number: 20110182905Abstract: Disclosed herein are anti-hGM-CSF monoclonal antibodies and antigen-binding fragments of such antibodies, with improved neutralizing capacity to hGM-CSF activity. Pharmaceutical compositions comprising such an antibody or antigen-binding fragment are also provided. The present invention is useful for the treatment of various diseases that are associated with aberrant expression of hGM-CSF.Type: ApplicationFiled: November 12, 2008Publication date: July 28, 2011Applicants: Evec Inc., Boehringer Ingelheim International GmbHInventors: Kenzo Takada, Kantou Nakajima, Barbara Kistler, John Park
-
Publication number: 20110182904Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, which specifically bind to BMP2, BMP4, BMPR1A, BMPR1B, ACTR1, and/or BMPR2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Also provided are immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention and, optionally, one or more additional therapeutic. The invention also provides methods for treating diseases associated with abnormal bone formation and ossification mediated by BMP2, BMP4, BMPR1A, BMPR1B, ACTR15 and/or BMPR2.Type: ApplicationFiled: September 5, 2007Publication date: July 28, 2011Inventors: Deborah Zimmerman, Mark Selby, Mohan Srinivasan, Alasdair Bell, Sujata Singh, Richard Theolis, Heidi N. Leblanc, Kyra D. Zens, Timothy William Sproul
-
Publication number: 20110182906Abstract: The present invention relates to the discovery and improvement of proteins that can specifically bind with human TNFa (Tumor Necrosis Factor alpha), the proteins are full human anti human TNFa monoclonal antibodies derived from human B cells. This invention disclosed the anti human TNFa monoclonal antibodies, their amino acid sequence of light chain comprising SEQ ID NO:8, and that of heavy chain comprising SEQ ID NO:16 or SEQ ID NO:18. This invention disclosed the coding genes of these antibodies, their Fab molecules, and their potential application to treat clinically the diseases related to TNFa, such as inflammation diseases.Type: ApplicationFiled: January 18, 2011Publication date: July 28, 2011Applicant: SHANGHAI PROGRAMMED ARTIFICIAL EVOLUTION CO., LTD.Inventor: Qingfa Liu
-
Patent number: 7982017Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: GrantFiled: December 18, 2008Date of Patent: July 19, 2011Assignee: BioAlliance C.V.Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
-
Patent number: 7977464Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.Type: GrantFiled: June 18, 2008Date of Patent: July 12, 2011Assignee: UCB Pharma S.A.Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
-
Publication number: 20110165063Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.Type: ApplicationFiled: October 21, 2010Publication date: July 7, 2011Applicant: ABBOTT LABORATORIESInventors: Chung-ming HSIEH, Chengbin WU
-
Patent number: 7968684Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: GrantFiled: November 12, 2004Date of Patent: June 28, 2011Assignee: Abbott LaboratoriesInventors: Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
-
Publication number: 20110150895Abstract: An antibody specifically binding to angiopoietin-2, and antigen-binding fragments thereof, and a use thereof are disclosed.Type: ApplicationFiled: December 15, 2010Publication date: June 23, 2011Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Jong-sang RYU, Brian Ho-sung MIN, A-yeon CHO, Min-kyung KIM
-
Patent number: 7964707Abstract: The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interlukin-2 (IL2), whereby said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to the human IL2 prior to, during, and/or subsequent to the binding of the human IL2 to the human IL2-receptor, and wherein the light chain variable region of the humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.Type: GrantFiled: May 31, 2006Date of Patent: June 21, 2011Assignee: Micromet AGInventors: Patrick Bäuerle, John Lumsden, Stefan Pflanz, Tobias Raum, Jörg Volkland
-
Patent number: 7964193Abstract: Antibodies directed to the antigen IL-1? and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: June 19, 2009Date of Patent: June 21, 2011Assignee: Amgen Fremont Inc.Inventors: Larry Green, Raffaella Faggioni, Orit Foord, Scott L. Klakamp, Giorgio Senaldi, Amy K. Schneider
-
Patent number: 7964711Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.Type: GrantFiled: October 26, 2009Date of Patent: June 21, 2011Assignee: ZymoGenetics, Inc.Inventors: Mark W. Rixon, Jane A. Gross
-
Publication number: 20110142761Abstract: The present invention describes IL-1? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1?. Binding proteins of the invention have high affinity for IL-1? and neutralize IL-1? activity. A binding protein of the invention can be a full-length antibody or an IL-1?-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1? binding proteins of the invention are useful for detecting IL-1? and for inhibiting IL-1? activity, including in a human subject suffering from a disease or disorder in which IL-1? activity is detrimental.Type: ApplicationFiled: October 15, 2010Publication date: June 16, 2011Applicant: ABBOTT LABORATORIESInventors: Chengbin Wu, Chung-ming Hsieh, Renee Miller, Dominic J. Ambrosi
-
Publication number: 20110142846Abstract: The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3.Type: ApplicationFiled: March 20, 2009Publication date: June 16, 2011Applicant: Indiana University Research and Technology CorporationInventors: Matthias Clauss, Irna Petrache, Robert Voswinckel
-
Publication number: 20110136172Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.Type: ApplicationFiled: February 10, 2011Publication date: June 9, 2011Applicant: SCHERING CORPORATIONInventors: JACQUELINE C. TIMANS, STEFAN KARL-HEINZ PFLANZ, ROBERT A. KASTELEIN, J. FERNANDO BAZAN, DONNA RENNICK, RENE DE WAAL MALEFYT, JEANNE CHEUNG
-
Publication number: 20110135597Abstract: Provided are methods of treatment for skin disorders. In particular, treatment, the skin disorders are generally inflammatory skin disorders, including improper wound healing. Provided are methods of using of a cytokine molecule.Type: ApplicationFiled: February 14, 2011Publication date: June 9, 2011Applicant: Schering CorporationInventors: Edward P. Bowman, Shi-Juan Chen, Daniel J. Cua, Kevin W. Moore, Tatyana Churakova, Hong-Nhung Y. Nguyen, Jason R. Chan